CompanyGraphWhat stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2021, balance sheet FY2025, cash-flow statement FY2021. Each figure below is labelled with the year it comes from.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
575.10MUSDvs all stocks (USD)
Revenue (TTM)
31.90MUSDvs all stocks (USD)
52-Week Change
0.10%vs all stocks
Market Capitalization
575.10MUSDvs all stocks (USD)
Enterprise Value
569.96MUSDvs all stocks (USD)
Forward P/E
-69.32xvs Biotechnology peers
Price to Sales (TTM)
18.03xvs Biotechnology peers
Enterprise to Revenue
17.87xvs Biotechnology peers
Enterprise to EBITDA
-4.53xvs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-31.68%vs Biotechnology peers
Revenue (TTM)
31.90MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4567USDUpdated Jul 9, 2026Gross Profit (TTM)
31.60MUSDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
655.02KUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-1.08MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-131.75MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
31.90MUSDFY2021 · Dec 31, 2021Cost of Goods Sold
302.00KUSDFY2021 · Dec 31, 2021Gross Profit
31.60MUSDFY2021 · Dec 31, 2021Operating Income
-129.92MUSDvs all stocks (USD)
Pre-tax Income
-131.75MUSDFY2021 · Dec 31, 2021Net Income
-131.75MUSDFY2021 · Dec 31, 2021EBITDA (Income Statement)
-125.92MUSDFY2021 · Dec 31, 2021Research & Development
82.99MUSDFY2021 · Dec 31, 2021Selling, General & Administrative
78.85MUSDFY2021 · Dec 31, 2021Other Operating Expenses
-324.00KUSDFY2021 · Dec 31, 2021Non-operating Interest Income
859.00KUSDFY2021 · Dec 31, 2021Non-operating Interest Expense
2.69MUSDFY2021 · Dec 31, 2021EPS (Basic)
-1.89USDFY2021 · Dec 31, 2021EPS (Diluted)
-1.89USDFY2021 · Dec 31, 2021Basic Shares Outstanding
69.85MSharesFY2021 · Dec 31, 2021Diluted Shares Outstanding
69.85MSharesFY2021 · Dec 31, 2021Net Income from Continuing Operations
-131.75MUSDFY2021 · Dec 31, 2021Operating Cash Flow
-77.29MUSDFY2021 · Dec 31, 2021Free Cash Flow
-96.31MUSDFY2021 · Dec 31, 2021Cash & Cash Equivalents (End of Period)
51.06MUSDFY2021 · Dec 31, 2021Interest Paid
2.03MUSDFY2021 · Dec 31, 2021Starting Profit (CF Statement)
-131.75MUSDFY2021 · Dec 31, 2021Depreciation & Amortization
3.14MUSDFY2021 · Dec 31, 2021Stock-based Compensation
30.69MUSDFY2021 · Dec 31, 2021Other Non-cash Items
5.93MUSDFY2021 · Dec 31, 2021Change in Accounts Receivable (CF)
-285.00KUSDFY2021 · Dec 31, 2021Change in Accounts Payable (CF)
2.61MUSDFY2021 · Dec 31, 2021Change in Other Assets/Liabilities
12.37MUSDFY2021 · Dec 31, 2021Capital Expenditures
-19.02MUSDFY2021 · Dec 31, 2021Purchase of Investments
-307.45MUSDFY2021 · Dec 31, 2021Sale of Investments
418.69MUSDFY2021 · Dec 31, 2021Net Investing Cash Flow
92.22MUSDFY2021 · Dec 31, 2021Long-term Debt Payments
-1.05MUSDFY2021 · Dec 31, 2021Net Short-term Debt Issuance
0.00USDFY2021 · Dec 31, 2021Other Financing Charges
-5.27MUSDFY2021 · Dec 31, 2021Net Financing Cash Flow
-6.32MUSDFY2021 · Dec 31, 2021Shares Outstanding
55.70MSharesUpdated Jul 9, 2026Float Shares
41.40MSharesUpdated Jul 9, 2026Shares Short
2.48KSharesUpdated Jul 9, 2026Short Ratio
0.1200daysvs all stocks
Short % of Shares Outstanding
0.01%vs all stocks
% Held by Insiders
1.19%vs all stocks
% Held by Institutions
76.28%vs all stocks
Total Cash (MRQ)
410.10KUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0070USDUpdated Jul 9, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Current Ratio (MRQ)
8.13xvs Biotechnology peers
Book Value per Share (MRQ)
-0.2540USDUpdated Jul 9, 2026Total Assets
415.91MUSDvs all stocks (USD)
Total Current Assets
1.06MUSDFY2025 · Dec 31, 2025Total Liabilities
16.12MUSDFY2025 · Dec 31, 2025Total Non-current Assets
414.85MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
15.99MUSDFY2025 · Dec 31, 2025Total Current Liabilities
130.67KUSDFY2025 · Dec 31, 2025Cash
736.20KUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
736.20KUSDFY2025 · Dec 31, 2025Common Stock (Book)
414.00MUSDFY2025 · Dec 31, 2025Retained Earnings
-14.21MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
399.79MUSDvs all stocks (USD)
52-Week Low
10.07USDUpdated Jul 9, 202652-Week High
11.13USDUpdated Jul 9, 202652-Week Change
0.10%vs all stocks
50-Day MA
10.23USDUpdated Jul 9, 2026200-Day MA
10.21USDUpdated Jul 9, 2026Avg 10-Day Volume
1.40KSharesUpdated Jul 9, 2026Avg 30-Day Volume
15.51KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-1.89USDUpdated Jul 9, 2026Other Income / Expense
-1.84MUSDFY2021 · Dec 31, 20211 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 655,025Operating Cash Flow (USD, TTM): -1,084,876
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zeria Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhuhai Rundu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Sunflower Great Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Beam Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC